Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. cut its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 43.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 145,510 shares of the company’s stock after selling 110,400 shares during the quarter. Prudential Financial Inc.’s holdings in Dyne Therapeutics were worth $3,428,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Quantbot Technologies LP acquired a new stake in Dyne Therapeutics during the third quarter valued at approximately $34,000. Point72 DIFC Ltd bought a new position in shares of Dyne Therapeutics in the third quarter valued at $36,000. KBC Group NV lifted its position in shares of Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after acquiring an additional 978 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Dyne Therapeutics during the 4th quarter worth $257,000. Finally, Magnetar Financial LLC acquired a new position in shares of Dyne Therapeutics in the 4th quarter worth $263,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $9.23 on Wednesday. Dyne Therapeutics, Inc. has a fifty-two week low of $9.17 and a fifty-two week high of $47.45. The stock’s 50-day moving average is $13.09 and its two-hundred day moving average is $23.06. The firm has a market cap of $1.04 billion, a P/E ratio of -2.59 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. As a group, research analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on DYN. BMO Capital Markets began coverage on Dyne Therapeutics in a report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 target price for the company. Robert W. Baird initiated coverage on shares of Dyne Therapeutics in a report on Friday, December 13th. They issued an “outperform” rating and a $46.00 target price for the company. JPMorgan Chase & Co. dropped their target price on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, March 21st. Chardan Capital restated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 17th. Finally, Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $47.46.

Insider Activity

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares of the company’s stock, valued at $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 6,237 shares of company stock worth $77,760. 20.77% of the stock is owned by corporate insiders.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.